ROQUEFORT THERAPEUTICS PLC

M&A Activity • Nov 12, 2021

National Storage Mechanism | Additional information

RNS Number : 2223S

Roquefort Investments PLC

12 November 2021

12 November 2021

Roquefort Investments plc

("Roquefort Investments" or the "Company")

Update on Acquisition of Lyramid Limited

Roquefort Investments (LSE:ROQ), the London listed investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, is pleased to announce that it has commenced marketing to potential investors to fund the acquisition and pre-clinical drug development programme of Lyramid Limited, details of which were announced on 29 September 2021.  A copy of the presentation is available on the Company's website at https://www.roquefortinvest.com/presentations

The Company looks forward to providing further updates in relation to the acquisition of Lyramid Limited as and when appropriate.

The Company's shares remain suspended from trading on the Main Market of the London Stock Exchange pending the publication of a Prospectus setting out full details of the potential transaction.

Enquiries:

Roquefort Investments plc
Stephen West (Chairman)	+44 (0)20 3290 9339
Optiva Securities Limited (Joint Broker)
Christian Dennis	+44 (0)20 3411 1881

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: ‎254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQBTBRTMTTBMLB